Can-Fite Biopharma (CANF) vs Lexaria Bioscience (LEXX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lexaria Bioscience is the larger company by market cap ($6.7 million vs $6.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CANF | LEXX |
|---|---|---|
| Share price | $2.00 | $3.20 |
| Market cap | $6.06M | $6.74M |
| 1-day change | -4.76% | -8.57% |
| YTD return | -46.50% | — |
| 1-year return | -82.17% | — |
| 5-year return | -99.31% | — |
| EPS (TTM) | $-13.23 | $-5.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.40 | $21.60 |
| 52-week low | $1.96 | $2.77 |
| Distance from 52-week high | -83.87% | -85.19% |
| Average volume | 387.60K | 62.08K |
| Shares outstanding | 3.03M | 2.11M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
CANF vs LEXX FAQ
Which is bigger, Can-Fite Biopharma or Lexaria Bioscience?
Lexaria Bioscience (LEXX) is larger, with a market capitalization of $6.74M compared with $6.06M for Can-Fite Biopharma (CANF).
Are Can-Fite Biopharma and Lexaria Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.